Enliven Therapeutics, Inc. (ELVN)
16.86
-1.91
(-10.18%)
USD |
NASDAQ |
Dec 12, 16:00
16.81
-0.05
(-0.30%)
After-Hours: 20:00
Enliven Therapeutics Total Liabilities (Quarterly): 14.75M for Sept. 30, 2025
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| CEL-SCI Corp. | 13.31M |
| AIM ImmunoTech, Inc. | 11.57M |
| IGC Pharma, Inc. | 1.651M |
| NovaBay Pharmaceuticals, Inc. | 1.853M |
| Protalix Biotherapeutics, Inc. | 29.36M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 490.88M |
| Shareholders Equity (Quarterly) | 476.12M |
| Debt to Equity Ratio | 0.0008 |
| Current Ratio | 32.95 |
| Net Debt Paydown Yield | -0.00% |